e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

153.44 -0.81 (-0.53%)

Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

55 56 Next >

Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off ↗

November 28, 2023

Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),...

Via Benzinga

Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028 ↗

November 27, 2023

Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory...

Via SBWire

Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. ↗

November 22, 2023

The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO.

Via Investor's Business Daily

2 overlooked stocks that crushed earnings but traded lower

November 20, 2023

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

Via MarketBeat

How Is The Market Feeling About Novartis? ↗

November 10, 2023

Via Benzinga

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Novartis Hikes Its Earnings Outlook For The Third Time This Year ↗

October 24, 2023

The company also beat third-quarter expectations after spinning off its Sandoz unit.

Via Investor's Business Daily

Earnings Outlook For Novartis ↗

October 23, 2023

Via Benzinga

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Diversifying Your Portfolio With Plant-Based Options ↗

November 16, 2023

Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market...

Via Talk Markets

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On ↗

November 16, 2023

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

Via The Motley Fool

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug ↗

November 13, 2023

Patients had big decreases in LDL cholesterol. But there were some side effects.

Via Investor's Business Daily

3 Spectacular High-Yield Dividend Stocks to Buy in November ↗

November 05, 2023

Income investors should find plenty to like with these stocks.

Via The Motley Fool

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

Via Investor Brand Network

Get Ready for Next Generation of Diabetes, Weight-Management Drugs

November 01, 2023

EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END

Via FinancialNewsMedia

Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study ↗

October 30, 2023

Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN). IgAN is a major cause of...

Via Benzinga

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

October 28, 2023

A couple of these stocks might not be available for under $100 for too much longer.

Via The Motley Fool

2 Green Flags and 1 Red Flag for Novartis Stock ↗

October 27, 2023

The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.

Via The Motley Fool

7 Undervalued Stocks to Buy Before Everyone Else ↗

October 26, 2023

Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations.

Via InvestorPlace

Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch ↗

October 24, 2023

Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.

Via Investor's Business Daily

Novartis Ag (NVS) Q3 2023 Earnings Call Transcript ↗

October 24, 2023

NVS earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline ↗

October 24, 2023

According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,...

Via SBWire

Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy

October 24, 2023

--News Direct--

Via News Direct

US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results ↗

October 24, 2023

Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day losing streak in the previous session. The uptick in...

Via Benzinga

Topics Bonds Stocks

Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More ↗

October 24, 2023

Novartis AG (NYSE: NVS) reported

Via Benzinga

Topics Earnings

Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market? ↗

October 23, 2023

Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.

Via Benzinga

Topics Stocks

7 Healthcare Stocks to invest in for a Healthy Future ↗

October 20, 2023

Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.

Via InvestorPlace

2 Biotech Stocks That Could Make You Richer ↗

October 17, 2023

These two well-known drugmakers still have some growth fuel in their seemingly empty tanks.

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy